ArticleThe European respiratory journal2013
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.
Article in The European respiratory journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019Guideline
- Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.International journal of molecular sciences · 2017Pooled it
- Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.International journal of molecular sciences · 2016Pooled it
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.Microorganisms · 2026Review
- Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.International journal of antimicrobial agents · 2023Article
- Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis.Open forum infectious diseases · 2022Article
- Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.Journal of the Pediatric Infectious Diseases Society · 2021Article
- Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.Molecules (Basel, Switzerland) · 2020Review
- Genetic polymorphisms of long noncoding RNA RP11-37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China.Journal of clinical laboratory analysis · 2019Article
- Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.PLoS medicine · 2019Observational
- The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Tuberculosis elimination: where are we now?European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.The European respiratory journal · 2018Article
- Article
- Clinical relevance ofOncotarget · 2017Article
- Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.Journal of thoracic disease · 2017Review
- The multidrug-resistant tuberculosis threat: old problems and new solutions.Journal of thoracic disease · 2015Article
- New anti-tuberculosis drugs and regimens: 2015 update.ERJ open research · 2015Review
- The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.The European respiratory journal · 2015Article
Corrections and comments
- Commented on by
- Commented on by
- Comment on
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23813314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.